Zevra Therapeutics, Inc.
ZVRA
$11.43
-$0.05-0.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 201.29% | 350.91% | 244.60% | 161.81% | 46.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.29% | 350.91% | 244.60% | 161.81% | 46.47% |
| Cost of Revenue | 98.37% | 122.22% | 124.35% | 239.77% | 286.28% |
| Gross Profit | 228.91% | 455.65% | 295.44% | 140.32% | 25.56% |
| SG&A Expenses | 22.34% | 41.50% | 35.56% | 66.06% | 70.75% |
| Depreciation & Amortization | -59.46% | -38.06% | -4.25% | 66.20% | 174.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.12% | 0.08% | 1.91% | 24.31% | 32.36% |
| Operating Income | 113.86% | 95.13% | 66.61% | 19.24% | -25.53% |
| Income Before Tax | 277.00% | 196.16% | 159.83% | 132.11% | -52.50% |
| Income Tax Expenses | -44.77% | -77.56% | -- | 10,494.35% | 50,272.73% |
| Earnings from Continuing Operations | 235.04% | 178.88% | 139.40% | 103.96% | -86.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 235.04% | 178.88% | 139.40% | 103.96% | -86.01% |
| EBIT | 113.86% | 95.13% | 66.61% | 19.24% | -25.53% |
| EBITDA | 119.47% | 99.78% | 70.91% | 23.97% | -19.41% |
| EPS Basic | 215.26% | 167.35% | 130.17% | 96.62% | -47.44% |
| Normalized Basic EPS | 117.70% | 108.67% | 79.19% | 34.14% | -22.36% |
| EPS Diluted | 204.80% | 159.55% | 122.60% | 87.37% | -48.00% |
| Normalized Diluted EPS | 117.00% | 108.22% | 79.19% | 34.14% | -22.36% |
| Average Basic Shares Outstanding | 14.32% | 19.61% | 28.26% | 33.76% | 32.29% |
| Average Diluted Shares Outstanding | 17.20% | 21.69% | 29.17% | 34.74% | 32.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |